

# Xbrane invites to a webcast today Tuesday, July 25th, 2023

**Stockholm, Sverige – Xbrane (Nasdaq: XBRANE); By reason of the press-release as of this morning, Xbrane invites analysts, investors and media to a webcast today Tuesday July 25th, 2023, at 11 a.m. CET.**

Martin Amark, CEO, will present a company update and respond to questions.

If you wish to participate via webcast, please use the link below. Via the webcast are you able to ask written questions.

<https://ir.financialhearings.com/xbrane-press-conference-2023/register>

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

<https://conference.financialhearings.com/teleconference/?id-5006354>

Following the event a recorded version of the webcast can be found on the company's website, [www.xbrane.com](http://www.xbrane.com).

## Contacts

Martin Åmark, CEO

M: +46 76 309 37 77

E: [martin.amark@xbrane.com](mailto:martin.amark@xbrane.com)

Anette Lindqvist, CFO/IR

M: +46 76 325 60 90

E: [anette.lindqvist@xbrane.com](mailto:anette.lindqvist@xbrane.com)

## About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 53 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during the first quarter 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit [www.xbrane.com](http://www.xbrane.com)

Press Release  
25 July 2023 08:05:00 CEST

---



## Attachments

---

[Xbrane invites to a webcast today Tuesday, July 25th, 2023](#)